Group One Trading
DMAC icon

Group One Trading’s DiaMedica Therapeutics DMAC Stock Holding History

Group One Trading’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19K Sell
2,800
-4,600
-62% -$36.4K ﹤0.01% 6002
2025
Q4 		$58.9K Buy
7,400
+4,700
+174% +$35.1K ﹤0.01% 5464
2025
Q3 		$18.5K Buy
2,700
+1,400
+108% +$7.59K ﹤0.01% 6752
2025
Q2 		$5.07K Buy
+1,300
New +$5.07K ﹤0.01% 7079
2024
Q2 		– Sell
-4,700
Closed -$13K – 6875
2024
Q1 		$13K Buy
4,700
+4,500
+2,250% +$13.1K ﹤0.01% 5709
2023
Q4 		$568 Sell
200
-6,800
-97% -$16.8K ﹤0.01% 7075
2023
Q3 		$18.1K Sell
7,000
-100
-1% -$321 ﹤0.01% 5955
2023
Q2 		$30.7K Hold
7,100
– – ﹤0.01% 5664
2023
Q1 		$10.9K Buy
+7,100
New +$11.3K ﹤0.01% 5892
2022
Q4 		– Sell
-6,900
Closed -$9K – 7408
2022
Q3 		$9K Sell
6,900
-2,700
-28% -$4.22K ﹤0.01% 6551
2022
Q2 		$19K Buy
9,600
+6,500
+210% +$15.2K ﹤0.01% 6322
2022
Q1 		$8K Buy
3,100
+1,300
+72% +$3.69K ﹤0.01% 7237
2021
Q4 		$7K Sell
1,800
-1,000
-36% -$3.93K ﹤0.01% 7511
2021
Q3 		$11K Buy
2,800
+1,700
+155% +$6.51K ﹤0.01% 7451
2021
Q2 		$5K Buy
+1,100
New +$9.02K ﹤0.01% 7753

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Group One Trading's DMAC Position: Q1 2026 in Review

Group One Trading reduced its DiaMedica Therapeutics (DMAC) stake by 3.4% in Q1 2026, selling an estimated $372 and leaving 1,342 shares worth $9.09K. The position accounts for ﹤0.01% of the portfolio, ranked #6419.

Group One Trading first reported a position in DMAC in Q2 2021 and has held it in 9 quarters since. The position peaked at $126K in Q4 2021. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Group One Trading held 1,342 shares of DiaMedica Therapeutics worth $9.09K as of Q1 2026.
  • Group One Trading sold 47 DiaMedica Therapeutics shares in Q1 2026, an estimated $372.
  • DiaMedica Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6419 holding.
  • Group One Trading first reported a position in DiaMedica Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Group One Trading's DiaMedica Therapeutics position peaked at $126K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.